Scarica l'app Stockscreener
3.46
0.00%
0.00
Precedente Chiudi:
$3.46
Aprire:
$3.48
Volume 24 ore:
4.24M
Relative Volume:
1.28
Capitalizzazione di mercato:
$786.74M
Reddito:
-
Utile/perdita netta:
$-179.82M
Rapporto P/E:
-2.6015
EPS:
-1.33
Flusso di cassa netto:
$-159.16M
1 W Prestazione:
+17.69%
1M Prestazione:
+79.27%
6M Prestazione:
+158.21%
1 anno Prestazione:
+293.18%
Intervallo 1D:
$3.3591
$3.60
Intervallo di 1 settimana:
$2.61
$3.60
Portata 52W:
$0.6617
$3.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Nome
Gossamer Bio Inc
Settore
Industria
Telefono
(858) 684-1300
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO, CA
Confronta GOSS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
3.46 | 707.15M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-05 | Ripresa | Wedbush | Outperform |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-03-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-12-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | JP Morgan | Neutral |
| 2022-09-19 | Iniziato | Wedbush | Outperform |
| 2022-04-18 | Iniziato | Raymond James | Outperform |
| 2022-04-06 | Iniziato | UBS | Buy |
| 2022-01-10 | Aggiornamento | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Ripresa | Piper Sandler | Overweight |
| 2020-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-30 | Iniziato | Berenberg | Buy |
| 2019-03-05 | Iniziato | Barclays | Overweight |
| 2019-03-05 | Iniziato | BofA/Merrill | Buy |
| 2019-03-05 | Iniziato | Evercore ISI | Outperform |
| 2019-03-05 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
Gossamer Bio (GOSS) Is Up 17.7% After Seralutinib Gains Key FDA Support and Clinical Progress - sg.finance.yahoo.com
Gossamer Bio's (GOSS) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Gossamer Bio, Inc. $GOSS Shares Sold by Siren L.L.C. - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
RSI Crosses Above 30 for Gossamer Bio Inc. — Reversal in SightEarnings Recap Summary & Reliable Price Action Trade Plans - Newser
Can swing trading help recover from Gossamer Bio Inc. lossesPortfolio Value Report & Low Drawdown Trading Strategies - Newser
Gossamer Bio (NASDAQ:GOSS) Shares Gap UpTime to Buy? - MarketBeat
Gossamer Bio Sees Unusually High Options Volume (NASDAQ:GOSS) - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Analysts - MarketBeat
What earnings revisions data tells us about Gossamer Bio Inc.2025 Key Lessons & Weekly High Potential Stock Alerts - Newser
Has Gossamer Bio Inc. found a price floorPortfolio Growth Summary & Accurate Buy Signal Notifications - Newser
Tick level data insight on Gossamer Bio Inc. volatilityTrade Volume Summary & Entry Point Strategy Guides - Newser
Using AI based signals to follow Gossamer Bio Inc.Quarterly Profit Report & Weekly High Conviction Ideas - Newser
Chart based analysis of Gossamer Bio Inc. trendsWeekly Stock Recap & Daily Profit Maximizing Tips - Newser
Combining machine learning predictions for Gossamer Bio Inc.Quarterly Investment Review & Weekly Watchlist of Top Performers - Newser
Detecting support and resistance levels for Gossamer Bio Inc.Quarterly Growth Report & Stepwise Trade Signal Guides - Newser
Is Gossamer Bio Inc. forming a bottoming baseQuarterly Growth Report & Free Safe Capital Growth Stock Tips - Newser
Analyzing recovery setups for Gossamer Bio Inc. investorsStop Loss & Verified Short-Term Trading Plans - Newser
Analyzing drawdowns of Gossamer Bio Inc. with statistical toolsNew Guidance & Smart Money Movement Alerts - Newser
How to recover losses in Gossamer Bio Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
Should you hold or exit Gossamer Bio Inc. nowEarnings Risk Report & Expert Approved Trade Ideas - Newser
Is Gossamer Bio Inc. building a consolidation basePortfolio Performance Summary & Stepwise Trade Execution Plans - Newser
Alyeska Investment Group L.P. Has $4.58 Million Holdings in Gossamer Bio, Inc. $GOSS - MarketBeat
What high frequency data says about Gossamer Bio Inc2025 Key Lessons & Fast Exit and Entry Trade Guides - Newser
Using Python tools to backtest Gossamer Bio Inc. strategiesQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - Newser
How to manage a losing position in Gossamer Bio Inc.Weekly Market Report & Precise Entry and Exit Recommendations - Newser
H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects - Yahoo Finance
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock - Investing.com
What’s the recovery path for long term holders of Gossamer Bio Inc.2025 Investor Takeaways & Real-Time Chart Breakout Alerts - Newser
Gossamer Bio (NASDAQ:GOSS) Reaches New 52-Week HighHere's Why - MarketBeat
Will breakout in Gossamer Bio Inc. lead to full recoveryJuly 2025 Trends & Low Risk Profit Maximizing Plans - Newser
Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case - Insider Monkey
Can Gossamer Bio Inc. hit a new high this month2025 Top Gainers & Smart Allocation Stock Tips - Newser
Investors Purchase Large Volume of Gossamer Bio Call Options (NASDAQ:GOSS) - Defense World
Price momentum metrics for Gossamer Bio Inc. explained2025 Trading Volume Trends & Growth-Oriented Investment Plans - Newser
Sector ETF performance correlation with Gossamer Bio Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Short interest data insights for Gossamer Bio Inc.Weekly Volume Report & Low Risk Entry Point Tips - Newser
Technical analysis overview for Gossamer Bio Inc. stockMarket Performance Report & High Accuracy Trade Alerts - Newser
Gossamer Bio (NASDAQ:GOSS) Shares Down 6%Here's What Happened - MarketBeat
Gossamer Bio announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Gossamer Bio Shares Rise After UBS Upgrade, PT Increase - MarketScreener
Gossamer Bio’s Bold Progress: Buy or Pass? - StocksToTrade
Gossamer Bio stock rating upgraded by UBS on PAH trial optimism - Investing.com Nigeria
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
What moving averages say about Gossamer Bio Inc.Portfolio Performance Summary & Smart Money Movement Tracker - Newser
UBS Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Raises Target Price to $9 - 富途牛牛
Using data models to predict Gossamer Bio Inc. stock movementTrade Risk Report & Fast Entry High Yield Stock Tips - Newser
How to use a screener to detect Gossamer Bio Inc. breakoutsQuarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
How moving averages guide Gossamer Bio Inc. tradingJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - Newser
Long term hold vs stop loss in Gossamer Bio Inc.Earnings Recap Report & AI Based Buy and Sell Signals - Newser
Gossamer Bio Inc Azioni (GOSS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):